

V REFERENCES

1. Weinstock, M.A. 1998. Issues in the epidemiology of melanoma. *Hematol Oncol Clin North Am* 12:681-98.
2. Jhappan, C., F.P. Noonan, and G. Merlino. 2003. Ultraviolet radiation and cutaneous malignant melanoma. *Oncogene* 22:3099-112.
3. Tucker, M.A., and A.M. Goldstein. 2003. Melanoma etiology: where are we? *Oncogene* 22:3042-52.
4. Ford, D., J.M. Bliss, A.J. Swerdlow, B.K. Armstrong, S. Franceschi, A. Green, E.A. Holly, T. Mack, R.M. MacKie, A. Osterlind, and et al. 1995. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). *Int J Cancer* 62:377-81.
5. Grulich, A.E., V. Bataille, A.J. Swerdlow, J.A. Newton-Bishop, J. Cuzick, P. Hersey, and W.H. McCarthy. 1996. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. *Int J Cancer* 67:485-91.
6. Bliss, J.M., D. Ford, A.J. Swerdlow, B.K. Armstrong, M. Cristofolini, J.M. Elwood, A. Green, E.A. Holly, T. Mack, R.M. MacKie, and et al. 1995. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). *Int J Cancer* 62:367-76.
7. Kefford, R.F., J.A. Newton Bishop, W. Bergman, and M.A. Tucker. 1999. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. *J Clin Oncol* 17:3245-51.
8. Bataille, V. 2003. Genetic epidemiology of melanoma. *Eur J Cancer* 39:1341-7.
9. Kadekaro, A.L., H. Kanto, R. Kavanagh, and Z.A. Abdel-Malek. 2003. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. *Ann N Y Acad Sci* 994:359-65.
10. Davies, H., G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, and P.A. Futreal. 2002. Mutations of the BRAF gene in human cancer. *Nature* 417:949-54.
11. Pollock, P.M., U.L. Harper, K.S. Hansen, L.M. Yudt, M. Stark, C.M. Robbins, T.Y. Moses, G. Hostetter, U. Wagner, J. Kakareka, G. Salem, T. Pohida, P. Heenan, P. Duray, O. Kallioniemi, N.K. Hayward, J.M. Trent, and P.S. Meltzer. 2003. High frequency of BRAF mutations in nevi. *Nat Genet* 33:19-20.
12. Curtin, J.A., J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, H. Kutzner, K.H. Cho, S. Aiba, E.B. Bocker, P.E. LeBoit, D. Pinkel, and B.C. Bastian. 2005. Distinct sets of genetic alterations in melanoma. *N Engl J Med* 353:2135-47.
13. Landi, M.T., J. Bauer, R.M. Pfeiffer, D.E. Elder, B. Hulley, P. Minghetti, D. Calista, P.A. Kanetsky, D. Pinkel, and B.C. Bastian. 2006. MC1R germline variants confer risk for BRAF-mutant melanoma. *Science* 313:521-2.
14. Gillanders, E., S.H. Juo, E.A. Holland, M. Jones, D. Nancarrow, D. Freas-Lutz, R. Sood, N. Park, M. Faruque, C. Markey, R.F. Kefford, J. Palmer, W. Bergman, D.T. Bishop, M.A. Tucker, B. Bressac-de Paillerets, J. Hansson, M. Stark, N. Gruis, J.N. Bishop, A.M. Goldstein, J.E. Bailey-Wilson, G.J. Mann, N. Hayward, and J. Trent. 2003. Localization of a novel melanoma susceptibility locus to 1p22. *Am J Hum Genet* 73:301-13.
15. Huijbers, I.J., P. Krimpenfort, P. Chomez, M.A. van der Valk, J.Y. Song, E.M. Inderberg-Suso, A.M. Schmitt-Verhulst, A. Berns, and B.J. Van den Eynde. 2006. An inducible mouse model of melanoma expressing a defined tumor antigen. *Cancer Res* 66:3278-86.
16. Balch, C.M., S.J. Soong, J.E. Gershenwald, J.F. Thompson, D.S. Reintgen, N. Cascinelli, M. Urist, K.M. McMasters, M.I. Ross, J.M. Kirkwood, M.B. Atkins, J.A. Thompson, D.G. Coit, D. Byrd, R. Desmond, Y. Zhang, P.Y. Liu, G.H. Lyman, and A. Morabito. 2001. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* 19:3622-34.
17. Balch, C.M., A.C. Buzaid, S.J. Soong, M.B. Atkins, N. Cascinelli, D.G. Coit, I.D. Fleming, J.E. Gershenwald, A. Houghton, Jr., J.M. Kirkwood, K.M. McMasters, M.F. Mihm, D.L. Morton, D.S. Reintgen, M.I. Ross, A. Sober, J.A. Thompson, and J.F. Thompson. 2001. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol* 19:3635-48.

18. Greene, F.L., D.L. Page, I.D. Fleming, A.G. Fritz, C.M. Balch, D.G. Haller, and M. Morrow, editors. 2002. *American Joint Committee on Cancer. Cancer Staging Manual*. 6th Edition ed. Springer, New York.
19. Balch, C.M., H. A.N., G.W. Milton, A.J. Sober, and S.J. Soong, editors. 1992. *Cutaneous Melanoma*. 2nd Edition ed. Edited by J.B.L. Company, Philadelphia.
20. Deichmann, M., A. Benner, M. Bock, A. Jackel, K. Uhl, V. Waldmann, and H. Naher. 1999. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. *J Clin Oncol* 17:1891-6.
21. Keilholz, U., P. Martus, C.J. Punt, W. Kruit, G. Mooser, D. Schadendorf, D. Liénard, R. Dummer, J. Koller, C. Voit, and A.M. Eggermont. 2002. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. *Eur J Cancer* 38:1501-11.
22. Morton, D.L., D.R. Wen, J.H. Wong, J.S. Economou, L.A. Cagle, F.K. Storm, L.J. Foshag, and A.J. Cochran. 1992. Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg* 127:392-9.
23. Gershenwald, J.E., W. Thompson, P.F. Mansfield, J.E. Lee, M.I. Colome, C.H. Tseng, J.J. Lee, C.M. Balch, D.S. Reintgen, and M.I. Ross. 1999. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. *J Clin Oncol* 17:976-83.
24. Vuylsteke, R.J., P.A. van Leeuwen, M.G. Statius Muller, H.A. Gietema, D.R. Kragt, and S. Meijer. 2003. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. *J Clin Oncol* 21:1057-65.
25. Dewar, D.J., B. Newell, M.A. Green, A.P. Topping, B.W. Powell, and M.G. Cook. 2004. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. *J Clin Oncol* 22:3345-9.
26. Lee, J.H., R. Essner, H. Torisu-Itakura, L. Wanek, H. Wang, and D.L. Morton. 2004. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. *J Clin Oncol* 22:3677-84.
27. Morton, D.L., J.F. Thompson, R. Essner, R. Elashoff, S.L. Stern, O.E. Nieweg, D.F. Roses, C.P. Karakousis, N. Mozzillo, D. Reintgen, H.J. Wang, E.C. Glass, and A.J. Cochran. 1999. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. *Ann Surg* 230:453-63; discussion 463-5.
28. McMasters, K.M., R.D. Noyes, D.S. Reintgen, J.S. Goydos, P.D. Beitsch, B.S. Davidson, J.J. Sussman, J.E. Gershenwald, and M.I. Ross. 2004. Lessons learned from the Sunbelt Melanoma Trial. *J Surg Oncol* 86:212-23.
29. Morton, D.L., J.F. Thompson, A.J. Cochran, R. Essner, and E.M.S.L.T. Group. 2005. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma. *Journal of Clinical Oncology* 23:7500 (abstract).
30. Balch, C.M., H. A.N., G.W. Milton, A. Sober, and S.J. Soong, editors. 2003. *Cutaneous Melanoma*. 4th Edition ed. Edited by I. Quality Medical Publishing, St Louis, Missouri.
31. Lienard, D., P. Ewalenko, J.J. Delmotte, N. Renard, and F.J. Lejeune. 1992. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. *J Clin Oncol* 10:52-60.
32. Liénard, D., A.M. Eggermont, H.S. Koops, B. Kroon, G. Towse, S. Hiemstra, P. Schmitz, J. Clarke, G. Steinmann, F. Rosenkaimer, and F.J. Lejeune. 1999. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. *Melanoma Res* 9:491-502.
33. Lejeune, F.J., C. Rüegg, and D. Liénard. 1998. Clinical applications of TNF-alpha in cancer. *Curr Opin Immunol* 10:573-80.
34. Lejeune, F.J., D. Lienard, M. Matter, and C. Ruegg. 2006. Efficiency of recombinant human TNF in human cancer therapy. *Cancer Immun* 6:6.
35. Helmbach, H., E. Rossmann, M.A. Kern, and D. Schadendorf. 2001. Drug-resistance in human melanoma. *Int J Cancer* 93:617-22.
36. Chin, L. 2003. The genetics of malignant melanoma: lessons from mouse and man. *Nat Rev Cancer* 3:559-70.
37. Middleton, M.R., J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich,

- M. Muller, and N. Thatcher. 2000. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 18:158-66.
38. Avril, M.F., S. Aamdal, J.J. Grob, A. Hauschild, P. Mohr, J.J. Bonerandi, M. Weichenthal, K. Neuber, T. Bieber, K. Gilde, V. Guillem Porta, J. Fra, J. Bonnetterre, P. Saiag, D. Kamanabrou, H. Pehamberger, J. Sufliarsky, J.L. Gonzalez Larriba, A. Scherrer, and Y. Menu. 2004. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. *J Clin Oncol* 22:1118-25.
39. Frantz, S. 2004. Lessons learnt from Genasense's failure. *Nat Rev Drug Discov* 3:542-3.
40. Schadendorf, D., S. Ugurel, B. Schuler-Thurner, F.O. Nestle, A. Enk, E.B. Brossmer, S. Grabbe, W. Rittgen, L. Edler, A. Sucker, C. Zimpfer-Rechner, T. Berger, J. Kamarashev, G. Burg, H. Jonuleit, A. Tutenberg, J.C. Becker, P. Keikavoussi, E. Kampgen, and G. Schuler. 2006. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. *Ann Oncol* 17:563-70.
41. Agarwala, S.S., J.M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, B. Czarnetski, M. Atkins, A. Buzaid, D. Skarlos, and E.M. Rankin. 2004. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. *J Clin Oncol* 22:2101-7.
42. Hwu, W.J., S.E. Krown, J.H. Menell, K.S. Panageas, J. Merrell, L.A. Lamb, L.J. Williams, C.J. Quinn, T. Foster, P.B. Chapman, P.O. Livingston, J.D. Wolchok, and A.N. Houghton. 2003. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. *J Clin Oncol* 21:3351-6.
43. Luikart, S.D., G.T. Kennealey, and J.M. Kirkwood. 1984. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. *J Clin Oncol* 2:164-8.
44. Buzaid, A.C., A. Legha, R. Winn, R. Belt, T. Pollock, C. Wiseman, and L.G. Ensign. 1993. Cisplatin (C), Vinblastine (V), and Dacarbazine (D) (CVD) versus Dacarbazine alone in metastatic melanoma: Preliminary results of a phase III cancer community oncology program (CCOP) trial. *Proceedings of the American Society of Clinical Oncology* 12:389.
45. Chapman, P.B., L.H. Einhorn, M.L. Meyers, S. Saxman, A.N. Destro, K.S. Panageas, C.B. Begg, S.S. Agarwala, L.M. Schuchter, M.S. Ernstoff, A.N. Houghton, and J.M. Kirkwood. 1999. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol* 17:2745-51.
46. Legha, S.S., S. Ring, N. Papadopoulos, C. Plager, S. Chawla, and R. Benjamin. 1989. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. *Cancer* 64:2024-9.
47. Atkins, M.B., M.T. Lotze, J.P. Dutcher, R.I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S.A. Rosenberg. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 17:2105-16.
48. Agarwala, S.S., and J.M. Kirkwood. 1996. Interferons in melanoma. *Curr Opin Oncol* 8:167-74.
49. Siegel, J.P., and R.K. Puri. 1991. Interleukin-2 toxicity. *J Clin Oncol* 9:694-704.
50. Vial, T., and J. Descotes. 1995. Immune-mediated side-effects of cytokines in humans. *Toxicology* 105:31-57.
51. Van Gool, A.R., W.H. Kruit, F.K. Engels, G. Stoter, M. Bannink, and A.M. Eggermont. 2003. Neuropsychiatric side effects of interferon-alfa therapy. *Pharm World Sci* 25:11-20.
52. Legha, S.S., S. Ring, A. Bedikian, C. Plager, O. Eton, A.C. Buzaid, and N. Papadopoulos. 1996. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. *Ann Oncol* 7:827-35.
53. Khayat, D., C. Borel, J.M. Tourani, A. Benhammouda, E. Antoine, O. Rixe, E. Vuillemin, P.A. Bazex, L. Thill, R. Franks, G. Auclerc, C. Soubrane, P. Banzet, and M. Weil. 1993. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. *J Clin Oncol* 11:2173-80.
54. Buzaid, A.C., M. Colome, A. Bedikian, O. Eton, S.S. Legha, N. Papadopoulos, C. Plager, M. Ross, J.E. Lee, P. Mansfield, J. Rice, S. Ring, J.J. Lee, E. Strom, and R. Benjamin. 1998. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. *Melanoma Res* 8:549-56.
55. Gibbs, P., A. Iannucci, M. Becker, J. Allen, M. O'Driscoll, K. McDowell, P. Williams, P. Rosse, J. Murphy, and R. Gonzalez. 2000. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. *Melanoma Res* 10:171-9.
56. Legha, S.S., S. Ring, O. Eton, A. Bedikian, A.C. Buzaid, C. Plager, and N. Papadopoulos. 1998. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine,

- dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. *J Clin Oncol* 16:1752-9.
57. McDermott, D.F., J.W. Mier, D.P. Lawrence, M.R. van den Brink, M.A. Clancy, K.M. Rubin, and M.B. Atkins. 2000. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. *Clin Cancer Res* 6:2201-8.
 58. O'Day, S.J., G. Gammon, P.D. Boasberg, M.A. Martin, T.S. Kristedja, M. Guo, S. Stern, S. Edwards, P. Fournier, M. Weisberg, M. Cannon, N.W. Fawzy, T.D. Johnson, R. Essner, L.J. Foshag, and D.L. Morton. 1999. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. *J Clin Oncol* 17:2752-61.
 59. Sertoli, M.R., P. Queirolo, E. Bajetta, M. DelVecchio, G. Comella, L. Barduagni, M.G. Bernengo, S. Vecchio, D. Criscuolo, R. Bufalino, A. Morabito, and N. Cascinelli. 1999. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). *Melanoma Res* 9:503-9.
 60. Keilholz, U., C. Conradt, S.S. Legha, D. Khayat, C. Scheibenbogen, N. Thatcher, S.H. Goey, M. Gore, T. Dorval, B. Hancock, C.J. Punt, R. Dummer, M.F. Avril, E.B. Bröcker, A. Benhammouda, A.M. Eggermont, and M. Pritsch. 1998. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. *J Clin Oncol* 16:2921-9.
 61. Ahmann, D.L., E.T. Creagan, R.G. Hahn, J.H. Edmonson, H.F. Bisel, and D.J. Schaid. 1989. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. *Cancer* 63:224-7.
 62. Rosenberg, S.A., J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, D.R. Parkinson, C.A. Seipp, J.H. Einhorn, and D.E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. *JAMA* 271:907-13.
 63. Keilholz, U., S.H. Goey, C.J. Punt, T.M. Proebstle, R. Salzmann, C. Scheibenbogen, D. Schadendorf, D. Lienard, A. Enk, R. Dummer, B. Hantich, A.M. Geueke, and A.M. Eggermont. 1997. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. *J Clin Oncol* 15:2579-88.
 64. Keilholz, U., C.J. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, J. Thomas, T.M. Proebstle, A. Schmittel, D. Schadendorf, T. Velu, S. Negrier, U. Kleeberg, F. Lehman, S. Suci, and A.M. Eggermont. 2005. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. *J Clin Oncol* 23:6747-55.
 65. Ridolfi, R., V. Chiarion-Sileni, M. Guida, A. Romanini, R. Labianca, A. Freschi, G. Lo Re, R. Nortilli, S. Brugnara, P. Vitali, and O. Nanni. 2002. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. *J Clin Oncol* 20:1600-7.
 66. Patchell, R.A., P.A. Tibbs, W.F. Regine, R.J. Dempsey, M. Mohiuddin, R.J. Kryscio, W.R. Markesbery, K.A. Foon, and B. Young. 1998. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. *JAMA* 280:1485-9.
 67. Grob, J.J., J. Regis, R. Laurant, M. Delaunay, P. Wolkenstein, K. Paul, P. Souteyrand, M.C. Koeppel, X. Murraciale, J.C. Perragut, and J.J. Bonerandi. 1998. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. *Eur J Cancer* 34:1187-92.
 68. Kleeberg, U.R., S. Suci, E.B. Brocker, D.J. Ruiter, C. Chartier, D. Lienard, J. Marsden, D. Schadendorf, and A.M. Eggermont. 2004. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. *Eur J Cancer* 40:390-402.
 69. Kirkwood, J.M., M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum. 1996. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol* 14:7-17.
 70. Grob, J.J., B. Dreno, P. de la Salmonière, M. Delaunay, D. Cupissol, B. Guillot, P. Souteyrand, B. Sassolas, J.P. Cesarini, S. Lionnet, C. Lok, C. Chastang, and J.J. Bonerandi. 1998. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. *Lancet* 351:1905-10.
 71. Eggermont, A.M., S. Suci, R. MacKie, W. Ruka, A. Testori, W. Kruit, C.J. Punt, M. Delaunay, F. Sales, G. Groenewegen, D.J. Ruiter, I. Jagiello, K. Stoitchkov, U. Keilholz, and D. Lienard. 2005. Post-

- surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. *Lancet* 366:1189-96.
72. Gross, L. 1943. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. *Cancer Res*:326-33.
 73. Prehn, R.T., and J.M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. *J Natl Cancer Inst* 18:769-78.
 74. Klein, G., H.O. Sjogren, E. Klein, and K.E. Hellstrom. 1960. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. *Cancer Res* 20:1561-72.
 75. Sjögren, H.O., I. Hellström, and G. Klein. 1961. Resistance of polyoma virus-immunized mice to transplantation of established polyoma tumors. *Exp Cell Res*:204-8.
 76. Kripke, M.L., and M.S. Fisher. 1976. Immunologic parameters of ultraviolet carcinogenesis. *J Natl Cancer Inst* 57:211-5.
 77. Burnet, F.M. 1971. Immunological surveillance in neoplasia. *Transplant Rev* 7:3-25.
 78. Stutman, O. 1974. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. *Science* 183:534-6.
 79. Stutman, O. 1975. Immunodepression and malignancy. *Advances in Cancer Research* 22:261-422.
 80. Hewitt, H.B., E.R. Blake, and A.S. Walder. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. *Br J Cancer* 33:241-59.
 81. Boon, T., and O. Kellermann. 1977. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. *Proc Natl Acad Sci U S A* 74:272-5.
 82. Boon, T., and A. Van Pel. 1978. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. *Proc Natl Acad Sci U S A* 75:1519-23.
 83. Van Pel, A., and T. Boon. 1982. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. *Proc Natl Acad Sci U S A* 79:4718-22.
 84. Rouse, B.T., M. Rollinghoff, and N.L. Warner. 1972. Anti-theta serum-induced suppression of the cellular transfer of tumour-specific immunity to a syngeneic plasma cell tumour. *Nat New Biol* 238:116-7.
 85. Leclerc, J.C., E. Gomard, F. Plata, and J.P. Levy. 1973. Cell-mediated immune reaction against tumors induced by oncornaviruses. II. Nature of the effector cells in tumor-cell cytolysis. *Int J Cancer* 11:426-32.
 86. Brunner, K.T., H.R. MacDonald, and J.C. Cerottini. 1980. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells. *J Immunol* 124:1627-34.
 87. Boon, T., J. Van Snick, A. Van Pel, C. Uyttenhove, and M. Marchand. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. *J Exp Med* 152:1184-93.
 88. Cerottini, J.C., H.D. Engers, H.R. Macdonald, and T. Brunner. 1974. Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. *J Exp Med* 140:703-17.
 89. Maryanski, J.L., J. Van Snick, J.C. Cerottini, and T. Boon. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. *Eur J Immunol* 12:401-6.
 90. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. *J Exp Med* 157:1040-52.
 91. Maryanski, J.L., M. Marchand, C. Uyttenhove, and T. Boon. 1983. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. *Int J Cancer* 31:119-23.
 92. Zinkernagel, R.M., and P.C. Doherty. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature* 248:701-2.
 93. Babbitt, B.P., P.M. Allen, G. Matsueda, E. Haber, and E.R. Unanue. 1985. Binding of immunogenic peptides to Ia histocompatibility molecules. *Nature* 317:359-61.
 94. Townsend, A.R., J. Bastin, K. Gould, and G.G. Brownlee. 1986. Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence. *Nature* 324:575-7.
 95. Townsend, A.R., J. Rothbard, F.M. Gotch, G. Bahadur, D. Wraith, and A.J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. *Cell* 44:959-68.

96. Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley. 1987. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. *Nature* 329:512-8.
97. Boon, T., P.G. Coulie, P. van der Bruggen, and N. van Baren. 2000. Immunology of the cancer cell: T lymphocyte responses. 2nd ed. *In* Clinical Oncology. J.O.A. M.D. Abeloff, A.S. Lichter, J.E. Niederhuber, Churchill Livingstone, editor, New York. 158-173.
98. Van den Eynde, B., B. Lethé, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. *J Exp Med* 173:1373-84.
99. Brändle, D., J. Bilsborough, T. Rülcke, C. Uyttenhove, T. Boon, and B.J. Van den Eynde. 1998. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. *Eur J Immunol* 28:4010-9.
100. Lurquin, C., A. Van Pel, B. Mariame, E. De Plaen, J.P. Szikora, C. Janssens, M.J. Reddehase, J. Lejeune, and T. Boon. 1989. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. *Cell* 58:293-303.
101. Sibille, C., P. Chomez, C. Wildmann, A. Van Pel, E. De Plaen, J.L. Maryanski, V. de Bergeyck, and T. Boon. 1990. Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide. *J Exp Med* 172:35-45.
102. Baldo, M., M. Schiavon, P.A. Cicogna, P. Boccato, and F. Mazzoleni. 1992. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. *Plast Reconstr Surg* 90:1073-6.
103. Mackensen, A., G. Carcelain, S. Viel, M.C. Raynal, H. Michalaki, F. Triebel, J. Bosq, and T. Hercend. 1994. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. *J Clin Invest* 93:1397-402.
104. Zorn, E., and T. Hercend. 1999. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. *Eur J Immunol* 29:592-601.
105. Zorn, E., and T. Hercend. 1999. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. *Eur J Immunol* 29:602-7.
106. Hérin, M., C. Lemoine, P. Weynants, F. Vessière, A. Van Pel, A. Knuth, R. Devos, and T. Boon. 1987. Production of stable cytolytic T-cell clones directed against autologous human melanoma. *Int J Cancer* 39:390-6.
107. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P.F. Robbins, F.M. Marincola, M.L. Salgaller, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. *J Immunol* 154:2257-65.
108. Van den Eynde, B., P. Hainaut, M. Hérin, A. Knuth, C. Lemoine, P. Weynants, P. van der Bruggen, R. Fauchet, and T. Boon. 1989. Presence on a human melanoma of multiple antigens recognized by autologous CTL. *Int J Cancer* 44:634-40.
109. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 254:1643-7.
110. Traversari, C., P. van der Bruggen, I.F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. *J Exp Med* 176:1453-7.
111. Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethé, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 178:489-95.
112. Wölfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.H. Meyer zum Büschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. *Eur J Immunol* 24:759-64.
113. Coulie, P.G., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J.P. Szikora, J.C. Renauld, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 180:35-42.
114. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. *J Exp Med* 180:347-52.

115. Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K.H. Meyer zum Buschenfelde, and D. Beach. 1995. A p16^{INK4a}-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. *Science* 269:1281-4.
116. Boon, T., and B. Van den Eynde. 2000. Cancer vaccines: Cancer antigens, shared tumor-specific antigens. 3rd Ed. ed. In *Principles and Practice of the Biologic Therapy of Cancer*. S.A. Rosenberg, editor. JB Lippincott Williams & Wilkins, Philadelphia. 493-504.
117. Robbins, P.F. 2000. Cancer vaccines: Cancer antigens, differentiation antigens. 3rd ed. In *Principles and Practice of the Biologic Therapy of Cancer*. S.A. Rosenberg, editor. Lippincott Williams and Wilkins, Philadelphia. 504-514.
118. Van den Eynde, B., and P. van der Bruggen. 2006. Regularly updated. Peptide database of T-cell defined tumor antigens. URL: <http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm>.
119. Van den Eynde, B.J., and P. van der Bruggen. 1997. T cell defined tumor antigens. *Curr Opin Immunol* 9:684-93.
120. Coulie, P.G., F. Lehmann, B. Lethé, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. *Proc Natl Acad Sci U S A* 92:7976-80.
121. Hallez, S., P. Simon, F. Maudoux, J. Doyen, J.-C. Noel, B. A., X. Capelle, F. Buxant, I. Fayt, A.C. Lagrost, P. Hubert, C. Gerday, A. Burny, J. Boniver, J.-M. Foidart, P. Delvenne, and N. Jacobs. 2004. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. *Cancer Immunol Immunother* 53:642-50.
122. Takahashi, K., S. Shichijo, M. Noguchi, M. Hirohata, and K. Itoh. 1995. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. *Cancer Res* 55:3478-82.
123. Haas, G.G., Jr., O.J. D'Cruz, and L.E. De Bault. 1988. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. *Am J Reprod Immunol Microbiol* 18:47-51.
124. Uyttenhove, C., C. Godfraind, B. Lethé, A. Amar-Costesec, J.C. Renauld, T.F. Gajewski, M.T. Duffour, G. Warnier, T. Boon, and B.J. Van den Eynde. 1997. The expression of mouse gene *P1A* in testis does not prevent safe induction of cytolytic T cells against a *P1A*-encoded tumor antigen. *Int J Cancer* 70:349-56.
125. Lucas, S., E. De Plaen, and T. Boon. 2000. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. *Int J Cancer* 87:55-60.
126. Chomez, P., O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas. 2001. An overview of the MAGE gene family with the identification of all human members of the family. *Cancer Res* 61:5544-51.
127. De Smet, C., O. De Backer, I. Faraoni, C. Lurquin, F. Brasseur, and T. Boon. 1996. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. *Proc Natl Acad Sci U S A* 93:7149-53.
128. De Smet, C., C. Lurquin, B. Lethé, V. Martelange, and T. Boon. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. *Mol Cell Biol* 19:7327-35.
129. De Smet, C., A. Lorient, and T. Boon. 2004. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. *Mol Cell Biol* 24:4781-90.
130. Brasseur, F., D. Rimoldi, D. Liénard, B. Lethé, S. Carrel, F. Arienti, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, A. Vacca, M. Conese, T. Lahaye, G. Degiovanni, R. Deraemaeker, M. Beauduin, X. Sastre, E. Salamon, B. Dréno, E. Jäger, A. Knuth, C. Chevreau, S. Suci, J.M. Lachapelle, P. Pouillart, G. Parmiani, F. Lejeune, J.C. Cerottini, T. Boon, and M. Marchand. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. *Int J Cancer* 63:375-80.
131. De Plaen, E., K. Arden, C. Traversari, J.J. Gaforio, J.P. Szikora, C. De Smet, F. Brasseur, P. van der Bruggen, B. Lethé, C. Lurquin, R. Brasseur, P. Chomez, O. De Backer, W. Cavenee, and T. Boon. 1994. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. *Immunogenetics* 40:360-9.
132. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J Exp Med* 179:921-30.
133. van der Bruggen, P., J. Bastin, T. Gajewski, P.G. Coulie, P. Boël, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. *Eur J Immunol* 24:3038-43.
134. Kawashima, I., S.J. Hudson, V. Tsai, S. Southwood, K. Takesako, E. Appella, A. Sette, and E. Celis. 1998. The multi-epitope approach for immunotherapy for cancer: identification of several CTL

- epitopes from various tumor-associated antigens expressed on solid epithelial tumors. *Hum Immunol* 59:1-14.
135. Oiso, M., M. Eura, F. Katsura, M. Takiguchi, Y. Sobao, K. Masuyama, M. Nakashima, K. Itoh, and T. Ishikawa. 1999. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. *Int J Cancer* 81:387-94.
 136. Bilsborough, J., C. Panichelli, M.T. Duffour, G. Warnier, C. Lurquin, E.S. Schultz, K. Thielemans, J. Corthals, T. Boon, and P. van der Bruggen. 2002. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. *Tissue Antigens* 60:16-24.
 137. Schultz, E.S., Y. Zhang, R. Knowles, J. Tine, C. Traversari, T. Boon, and P. van der Bruggen. 2001. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. *Tissue Antigens* 57:103-9.
 138. Tanzarella, S., V. Russo, I. Lionello, P. Dalerba, D. Rigatti, C. Bordignon, and C. Traversari. 1999. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. *Cancer Res* 59:2668-74.
 139. Schultz, E.S., J. Chapiro, C. Lurquin, S. Claverol, O. Burlet-Schiltz, G. Warnier, V. Russo, S. Morel, F. Levy, T. Boon, B.J. Van den Eynde, and P. van der Bruggen. 2002. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. *J Exp Med* 195:391-9.
 140. Herman, J., P. van der Bruggen, I.F. Luescher, S. Mandruzzato, P. Romero, J. Thonnard, K. Fleischhauer, T. Boon, and P.G. Coulie. 1996. A peptide encoded by the human *MAGE3* gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing *MAGE3*. *Immunogenetics* 43:377-83.
 141. Russo, V., S. Tanzarella, P. Dalerba, D. Rigatti, P. Rovere, A. Villa, C. Bordignon, and C. Traversari. 2000. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. *Proc Natl Acad Sci U S A* 97:2185-90.
 142. Breckpot, K., C. Heirman, C. De Greef, P. van der Bruggen, and K. Thielemans. 2004. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. *J Immunol* 172:2232-7.
 143. Schultz, E.S., B. Lethé, C.L. Cambiaso, J. Van Snick, P. Chaux, J. Corthals, C. Heirman, K. Thielemans, T. Boon, and P. van der Bruggen. 2000. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. *Cancer Res* 60:6272-5.
 144. Schultz, E.S., B. Schuler-Thurner, V. Stroobant, L. Jenne, T.G. Berger, K. Thielemans, P. van der Bruggen, and G. Schuler. 2004. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. *J Immunol* 172:1304-10.
 145. Zhang, Y., P. Chaux, V. Stroobant, A.M. Eggermont, J. Corthals, B. Maillere, K. Thielemans, M. Marchand, T. Boon, and P. van der Bruggen. 2003. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. *J Immunol* 171:219-25.
 146. Kobayashi, H., Y. Song, D.S. Hoon, E. Appella, and E. Celis. 2001. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. *Cancer Res* 61:4773-8.
 147. Consogno, G., S. Manici, V. Facchinetti, A. Bachi, J. Hammer, B.M. Conti-Fine, C. Rugarli, C. Traversari, and M.P. Protti. 2003. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. *Blood* 101:1038-1044.
 148. Manici, S., T. Sturniolo, M.A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, and M.P. Protti. 1999. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. *J Exp Med* 189:871-6.
 149. Chaux, P., V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, R. Luiten, A.M. Eggermont, T. Boon, and P. van der Bruggen. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. *J Exp Med* 189:767-78.
 150. Chaux, P., R. Luiten, N. Demotte, V. Vantomme, V. Stroobant, C. Traversari, V. Russo, E. Schultz, G.R. Cornelis, T. Boon, and P. van der Bruggen. 1999. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. *J Immunol* 163:2928-36.
 151. Luiten, R.M., N. Demotte, J. Tine, and P. van der Bruggen. 2000. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. *Tissue Antigens* 56:77-81.
 152. Lucas, S., F. Brasseur, and T. Boon. 1999. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. *Cancer Res* 59:4100-3.

153. Amar-Costesec, A., D. Godelaine, E. Stockert, P. van der Bruggen, H. Beaufay, and Y.T. Chen. 1994. The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. *Biochem Biophys Res Commun* 204:710-5.
154. Laduron, S., R. Deplus, S. Zhou, O. Kholmanskikh, D. Godelaine, C. De Smet, S.D. Hayward, F. Fuks, T. Boon, and E. De Plaen. 2004. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. *Nucleic Acids Res* 32:4340-50.
155. Maruyama, K., M. Usami, T. Aizawa, and K. Yoshikawa. 1991. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells. *Biochem Biophys Res Commun* 178:291-6.
156. Salehi, A.H., P.P. Roux, C.J. Kubu, C. Zeindler, A. Bhakar, L.L. Tannis, J.M. Verdi, and P.A. Barker. 2000. NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. *Neuron* 27:279-88.
157. Türeci, Ö., U. Sahin, I. Schobert, M. Koslowski, H. Schmitt, H.J. Schild, F. Stenner, G. Seitz, H.G. Rammensee, and M. Pfreundschuh. 1996. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. *Cancer Res* 56:4766-72.
158. Chen, Y.T., M.J. Scanlan, U. Sahin, O. Tureci, A.O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L.J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. *Proc Natl Acad Sci U S A* 94:1914-8.
159. Türeci, Ö., U. Sahin, C. Zwick, M. Koslowski, G. Seitz, and M. Pfreundschuh. 1998. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. *Proc Natl Acad Sci U S A* 95:5211-6.
160. Aarnoudse, C.A., P.B. van den Doel, B. Heemskerk, and P.I. Schrier. 1999. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. *Int J Cancer* 82:442-8.
161. Liu, X.F., L.J. Helman, C. Yeung, T.K. Bera, B. Lee, and I. Pastan. 2000. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. *Cancer Res* 60:4752-5.
162. Martelange, V., C. De Smet, E. De Plaen, C. Lurquin, and T. Boon. 2000. Identification on a human sarcoma of two new genes with tumor-specific expression. *Cancer Res* 60:3848-55.
163. Guilloux, Y., S. Lucas, V.G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethé, F. Jotereau, and T. Boon. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. *J Exp Med* 183:1173-83.
164. Lupetti, R., P. Pissarra, A. Verrecchia, C. Farina, G. Nicolini, A. Anichini, C. Bordignon, M. Sensi, G. Parmiani, and C. Traversari. 1998. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. *J Exp Med* 188:1005-16.
165. Morel, S., A. Ooms, A. Van Pel, T. Wölfel, V.G. Brichard, P. van der Bruggen, B.J. Van den Eynde, and G. Degiovanni. 1999. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. *Int J Cancer* 83:755-9.
166. Brichard, V.G., J. Herman, A. Van Pel, C. Wildmann, B. Gaugler, T. Wölfel, T. Boon, and B. Lethé. 1996. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. *Eur J Immunol* 26:224-30.
167. Kobayashi, H., T. Kokubo, K. Sato, S. Kimura, K. Asano, H. Takahashi, H. Iizuka, N. Miyokawa, and M. Katagiri. 1998. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. *Cancer Res* 58:296-301.
168. Topalian, S.L., M.I. Gonzales, M. Parkhurst, Y.F. Li, S. Southwood, A. Sette, S.A. Rosenberg, and P.F. Robbins. 1996. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. *J Exp Med* 183:1965-71.
169. Zarour, H.M., J.M. Kirkwood, L.S. Kierstead, W. Herr, V. Brusic, C.L. Slingluff, Jr., J. Sidney, A. Sette, and W.J. Storkus. 2000. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. *Proc Natl Acad Sci U S A* 97:400-5.
170. Benlalam, H., B. Linard, Y. Guilloux, A. Moreau-Aubry, L. Derre, E. Diez, B. Dreno, F. Jotereau, and N. Labarrière. 2003. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. *J Immunol* 171:6283-9.
171. Le Gal, F.A., M.F. Avril, J. Bosq, P. Lefebvre, J.C. Deschemin, M. Andrieu, M.X. Dore, and J.G. Guillet. 2001. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. *J Invest Dermatol* 117:1464-70.

172. Bystryrn, J.C., D. Rigel, R.J. Friedman, and A. Kopf. 1987. Prognostic significance of hypopigmentation in malignant melanoma. *Arch Dermatol* 123:1053-5.
173. Koh, H.K., A.J. Sober, H. Nakagawa, D.M. Albert, M.C. Mihm, and T.B. Fitzpatrick. 1983. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. *J Am Acad Dermatol* 9:696-708.
174. Nordlund, J.J., J.M. Kirkwood, B.M. Forget, G. Milton, D.M. Albert, and A.B. Lerner. 1983. Vitiligo in patients with metastatic melanoma: a good prognostic sign. *J Am Acad Dermatol* 9:689-96.
175. Ludewig, B., A.F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R.M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. *J Exp Med* 191:795-804.
176. Ichikawa, H.T., L.P. Williams, and B.M. Segal. 2002. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. *J Immunol* 169:2781-7.
177. Chen, W., S. Khilko, J. Fecondo, D.H. Margulies, and J. McCluskey. 1994. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. *J Exp Med* 180:1471-83.
178. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature* 351:290-6.
179. Parkhurst, M.R., M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. *J Immunol* 157:2539-48.
180. Bakker, A.B., S.H. van der Burg, R.J. Huijbens, J.W. Drijfhout, C.J. Melief, G.J. Adema, and C.G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. *Int J Cancer* 70:302-9.
181. Valmori, D., J.F. Fonteneau, C.M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. *J Immunol* 160:1750-8.
182. Chen, J.L., P.R. Dunbar, U. Gileadi, E. Jager, S. Gnjjatic, Y. Nagata, E. Stockert, D.L. Panicali, Y.T. Chen, A. Knuth, L.J. Old, and V. Cerundolo. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. *J Immunol* 165:948-55.
183. Clay, T.M., M.C. Custer, M.D. McKee, M. Parkhurst, P.F. Robbins, K. Kerstann, J. Wunderlich, S.A. Rosenberg, and M.I. Nishimura. 1999. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. *J Immunol* 162:1749-55.
184. Dutoit, V., V. Rubio-Godoy, M.J. Pittet, A. Zippelius, P.Y. Dietrich, F.A. Legal, P. Guillaume, P. Romero, J.C. Cerottini, R.A. Houghten, C. Pinilla, and D. Valmori. 2002. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. *J Exp Med* 196:207-16.
185. Ayyoub, M., A. Zippelius, M.J. Pittet, D. Rimoldi, D. Valmori, J.C. Cerottini, P. Romero, F. Lejeune, D. Lienard, and D.E. Speiser. 2003. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. *Clin Cancer Res* 9:669-77.
186. Romero, P., V. Dutoit, V. Rubio-Godoy, D. Liénard, D. Speiser, P. Guillaume, K. Servis, D. Rimoldi, J.C. Cerottini, and D. Valmori. 2001. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. *Clin Cancer Res* 7:766s-772s.
187. Khong, H.T., J.C. Yang, S.L. Topalian, R.M. Sherry, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg. 2004. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. *J Immunother* 27:472-7.
188. Chen, J.L., G. Stewart-Jones, G. Bossi, N.M. Lissin, L. Wooldridge, E.M. Choi, G. Held, P.R. Dunbar, R.M. Esnouf, M. Sami, J.M. Boulter, P. Rizkallah, C. Renner, A. Sewell, P.A. van der Merwe, B.K. Jakobsen, G. Griffiths, E.Y. Jones, and V. Cerundolo. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. *J Exp Med* 201:1243-55.
189. Smith, J.W., 2nd, E.B. Walker, B.A. Fox, D. Haley, K.P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, J. Vetto, H. Maecker, A. Dols, S. Meijer, H.M. Hu, P. Romero, W.G. Alvord, and W.J. Urba. 2003. Adjuvant Immunization of HLA-A2-Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses. *J Clin Oncol* 21:1562-73.
190. Speiser, D.E., D. Lienard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A.M. Krieg, J.C. Cerottini, and P. Romero. 2005. Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *J Clin Invest*:739-746.

191. Aichele, P., D. Kyburz, P.S. Ohashi, B. Odermatt, R.M. Zinkernagel, H. Hengartner, and H. Pircher. 1994. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. *Proc Natl Acad Sci U S A* 91:444-8.
192. Toes, R.E.M., E.I.H. van der Voort, S.P. Schoenberger, J.W. Drijfhout, L. van Bloois, G. Storm, W.M. Kast, R. Offringa, and C.J.M. Melief. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. *J Immunol* 160:4449-4456.
193. Beahrs, O.H., D.E. Henson, R.V.P. Hutter, and B.J. Kennedy, editors. 1992. *American Joint Committee on Cancer. Manual for staging of cancer*. 4th Edition ed. J.B. Lippincott Company, Philadelphia.
194. Fleming, I.D., J.S. Cooper, D.E. Henson, R.V.P. Hutter, B.J. Kennedy, G. Murphy, B. O'Sullivan, L.H. Sobin, and J.W. Yarbro, editors. 1997. *American Joint Committee on Cancer. Cancer Staging Manual*. 5th Edition ed. Lippincott-Raven, Philadelphia.
195. Weynants, P., B. Lethé, F. Brasseur, M. Marchand, and T. Boon. 1994. Expression of MAGE genes by non-small-cell lung carcinomas. *Int J Cancer* 56:826-9.
196. Lethé, B., P. van der Bruggen, F. Brasseur, and T. Boon. 1997. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. *Melanoma Res* 7 Suppl 2:S83-8.
197. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dréno, M.H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, A. Bourlond, R. Vanwijck, D. Liénard, M. Beauduin, P.Y. Dietrich, V. Russo, J. Kerger, G. Masucci, E. Jager, J. De Greve, J. Atzpodien, F. Brasseur, P.G. Coulie, P. van der Bruggen, and T. Boon. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 80:219-30.
198. Marchand, M., C.J. Punt, S. Aamdal, B. Escudier, W.H. Kruit, U. Keilholz, L. Hakansson, N. van Baren, Y. Humblet, P. Mulders, M.F. Avril, A.M. Eggermont, C. Scheibenbogen, J. Uiters, J. Wanders, M. Delire, T. Boon, and G. Stoter. 2003. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. *Eur J Cancer* 39:70-7.
199. Brichard, V.G., G. Warnier, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. *Eur J Immunol* 25:664-71.
200. World Health Organization Handbook for reporting results of cancer treatment. 1979. Vol. 48. WHO Offset Publication, Geneva.
201. Miller, A.B., B. Hogestraeten, M. Staquet, and A. Winkler. 1981. Reporting results of cancer treatment. *Cancer* 47:207-14.
202. Therasse, P., S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian, and S.G. Gwyther. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-16.
203. Storkus, W.J., D.N. Howell, R.D. Salter, J.R. Dawson, and P. Cresswell. 1987. NK susceptibility varies inversely with target cell class I HLA antigen expression. *J Immunol* 138:1657-9.
204. Chaux, P., V. Vantomme, P. Coulie, T. Boon, and P. van der Bruggen. 1998. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. *Int J Cancer* 77:538-42.
205. Coulie, P.G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. *Proc Natl Acad Sci U S A* 98:10290-5.
206. Altman, J.D., P.A.H. Moss, P.J.R. Goulder, D.H. Barouch, M.G. McHeyzer-Williams, J.I. Bell, A.J. McMichael, and M.M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. *Science* 274:94-96.
207. Zhang, Y., Z. Sun, H. Nicolay, R.G. Meyer, N. Renkvist, V. Stroobant, J. Corthals, J. Carrasco, A.M. Eggermont, M. Marchand, K. Thielemans, T. Wolfel, T. Boon, and P. van der Bruggen. 2005. Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein. *J Immunol* 174:2404-11.
208. Vantomme, V., C. Dantinne, N. Amrani, P. Permanné, D. Gheysen, C. Bruck, G. Stoter, C.M. Britten, U. Keilholz, C.H. Lamers, M. Marchand, M. Delire, and M. Gueguen. 2004. Immunological analysis of a phase I/II study of vaccination with a MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3 positive tumors. *J Immunother* 27:124-135.

209. Stockert, E., E. Jager, Y.T. Chen, M.J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L.J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. *J Exp Med* 187:1349-54.
210. Kruit, W.H., H.H. van Ojik, V.G. Brichard, B. Escudier, T. Dorval, B. Dreno, P. Patel, N. van Baren, M.F. Avril, S. Piperno, A. Khammari, M. Stas, G. Ritter, B. Lethe, D. Godelaine, F. Brasseur, Y. Zhang, P. van der Bruggen, T. Boon, A.M. Eggermont, and M. Marchand. 2005. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. *Int J Cancer* 117:596-604.
211. Pascolo, S., M. Schirle, B. Guckel, T. Dumrese, S. Stumm, S. Kayser, A. Moris, D. Wallwiener, H.G. Rammensee, S. Stevanovic, K.Y. Tsang, M. Zhu, J. Even, J. Gulley, P. Arlen, and J. Schlom. 2001. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. *Cancer Res* 61:4072-7.
212. Ottaviani, S., Y. Zhang, T. Boon, and P. van der Bruggen. 2005. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. *Cancer Immunol Immunother* 54:1214-20.
213. Duffour, M.T., P. Chaux, C. Lurquin, G. Cornelis, T. Boon, and P. van der Bruggen. 1999. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. *Eur J Immunol* 29:3329-37.
214. Huang, L.Q., F. Brasseur, A. Serrano, E. De Plaen, P. van der Bruggen, T. Boon, and A. Van Pel. 1999. Cytolytic T lymphocytes recognize an antigen encoded by *MAGE-A10* on a human melanoma. *J Immunol* 162:6849-54.
215. Ma, W., C. Germeau, N. Vigneron, A.S. Maernoudt, S. Morel, T. Boon, P.G. Coulie, and B. Van den Eynde. 2004. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. *Int J Cancer* 109:698-702.
216. van der Bruggen, P., J.P. Szikora, P. Boël, C. Wildmann, M. Somville, M. Sensi, and T. Boon. 1994. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. *Eur J Immunol* 24:2134-40.
217. Nishiyama, T., M. Tachibana, Y. Horiguchi, K. Nakamura, Y. Ikeda, K. Takesako, and M. Murai. 2001. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. *Clin Cancer Res* 7:23-31.
218. Heidecker, L., F. Brasseur, M. Probst-Kepper, M. Gueguen, T. Boon, and B.J. Van den Eynde. 2000. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. *J Immunol* 164:6041-5.
219. Panelli, M.C., M.P. Bettinotti, K. Lally, G.A. Ohnmacht, Y. Li, P. Robbins, A. Riker, S.A. Rosenberg, and F.M. Marincola. 2000. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. *J Immunol* 164:4382-92.
220. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J.L. Canon, C. Laurent, J.M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jäger, F. Brasseur, J. Herman, P.G. Coulie, and T. Boon. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. *Int J Cancer* 63:883-5.
221. van Baren, N., M.C. Bonnet, B. Dreno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Lienard, D. Speiser, M. Marchand, V.G. Brichard, B. Escudier, S. Negrier, P.Y. Dietrich, D. Maraninchi, S. Osanto, R.G. Meyer, G. Ritter, P. Moingeon, J. Tartaglia, P. van der Bruggen, P.G. Coulie, and T. Boon. 2005. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. *J Clin Oncol* 23:9008-21.
222. Kensil, C.R., U. Patel, M. Lennick, and D. Marciani. 1991. Separation and characterization of saponins with adjuvant activity from *Quillaja saponaria* Molina cortex. *J Immunol* 146:431-7.
223. Kensil, C.R., S. Soltysik, and U. Patel. 1992. Structure/function relationship in adjuvants from *Quillaja saponaria* Molina. Vaccines 92, eds. R.M. Channock, H.S. Ginsburg and F. Brown. Cold Spring Harbor Laboratory Press, New York. 36-40 pp.
224. Wu, J.Y., B.H. Gardner, C.I. Murphy, J.R. Seals, C.R. Kensil, J. Recchia, G.A. Beltz, G.W. Newman, and M.J. Newman. 1992. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. *J Immunol* 148:1519-25.
225. Newman, M.J., J.Y. Wu, B.H. Gardner, K.J. Munroe, D. Leombruno, J. Recchia, C.R. Kensil, and R.T. Coughlin. 1992. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. *J Immunol* 148:2357-62.
226. Ribí, E.e.a. 1986. Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A. In Immunobiology and Immunopharmacology of Bacterial Endotoxins. A. Szentivanyi and H. Friedman, editors. 1 vols. Plenum US (Press), New York. 407-20.
227. Chougnet, C., and G.M. Shearer. 1996. Potential clinical applications of interleukin-12. *Curr Opin Hematol* 3:216-22.

228. Fallarino, F., C. Uyttenhove, T. Boon, and T.F. Gajewski. 1999. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. *Int J Cancer* 80:324-33.
229. Gajewski, T.F., F. Fallarino, A. Ashikari, and M. Sherman. 2001. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. *Clin Cancer Res* 7:895s-901s.
230. Gérard, C.M., N. Baudson, K. Kraemer, C. Bruck, N. Garcon, Y. Paterson, Z.K. Pan, and D. Pardoll. 2001. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. *Vaccine* 19:2583-9.
231. Stoute, J.A., M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, P. Desmons, B.T. Wellde, N. Garcon, U. Krzych, and M. Marchand. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum* malaria. *N Engl J Med* 336:86-91.
232. Brichard, V.G., T. Dorval, R.J. Salmon, and e. al. 2001. Peptide-based immunization against tumor-specific antigen NA17.A2 in HLA-A2 patients with metastatic cutaneous or ocular melanoma. *Proc Am Ass Cancer Res* 42:699 (abstract nr #3760).
233. Weiner, G.J. 2000. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. *J Leukoc Biol* 68:455-63.
234. Dillman, R.O., C. DeLeon, L.D. Beutel, N.M. Barth, L.S. Schwartzberg, L.E. Spitler, D.H. Garfield, A.A. O'Connor, and S.K. Nayak. 2001. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. *Crit Rev Oncol Hematol* 39:115-23.
235. Berd, D., T. Sato, H. Cohn, H.C. Maguire, Jr., and M.J. Mastrangelo. 2001. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. *Int J Cancer* 94:531-9.
236. Krause, S.W., C. Neumann, A. Soruri, S. Mayer, J.H. Peters, and R. Andreesen. 2002. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. *J Immunother* 25:421-8.
237. Wei, Y., R.P. Sticca, L.M. Holmes, K.E. Burgin, J. Li, J. Williamson, L. Evans, S.J. Smith, J.J. Stephenson, and T.E. Wagner. 2006. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. *Int J Oncol* 28:585-93.
238. Trefzer, U., G. Herberth, K. Wohlan, A. Milling, M. Thiemann, T. Sherev, K. Sparbier, W. Sterry, and P. Walden. 2004. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. *Int J Cancer* 110:730-40.
239. Belli, F., A. Testori, L. Rivoltini, M. Maio, G. Andreola, M.R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, M. Carrabba, G. Scita, C. Santantonio, L. Pilla, G. Tragni, C. Lombardo, F. Arienti, A. Marchiano, P. Queirolo, F. Bertolini, A. Cova, E. Lamaj, L. Ascani, R. Camerini, M. Corsi, N. Cascinelli, J.J. Lewis, P. Srivastava, and G. Parmiani. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. *J Clin Oncol* 20:4169-80.
240. Livingston, P.O., H. Takeyama, M.S. Pollack, A.N. Houghton, A. Albino, C.M. Pinsky, H.F. Oettgen, and L.J. Old. 1983. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. *Int J Cancer* 31:567-75.
241. Weisenburger, T.H., P.C. Jones, S.S. Ahn, R.F. Irie, and G.J. Juillard. 1982. Active specific intralymphatic immunotherapy in metastatic malignant melanoma: evidence of clinical response. *J Biol Resp Modif* 1:57-66.
242. Morton, D.L., L.J. Foshag, D.S. Hoon, J.A. Nizze, L.A. Wanek, C. Chang, D.G. Davtyan, R.K. Gupta, R. Elashoff, and R.F. Irie. 1992. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. *Ann Surg* 216:463-82.
243. Hsueh, E.C., L. Nathanson, L.J. Foshag, R. Essner, J.A. Nizze, S.L. Stern, and D.L. Morton. 1999. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. *Cancer* 85:2160-9.
244. Mitchell, M.S., W. Harel, R.A. Kempf, E. Hu, J. Kan-Mitchell, W.D. Boswell, G. Dean, and L. Stevenson. 1990. Active-specific immunotherapy for melanoma. *J Clin Oncol* 8:856-69.
245. Mitchell, M.S., J. Kan-Mitchell, R.A. Kempf, W. Harel, H.Y. Shau, and S. Lind. 1988. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. *Cancer Res* 48:5883-93.
246. Vaishampayan, U., J. Abrams, D. Darrah, V. Jones, and M.S. Mitchell. 2002. Active Immunotherapy of Metastatic Melanoma with Allogeneic Melanoma Lysates and Interferon alpha. *Clin Cancer Res* 8:3696-701.

247. Mitchell, M.S., J. Kan-Mitchell, P.R. Morrow, D. Darrah, V.E. Jones, and M.F. Mescher. 2004. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. *Clin Cancer Res* 10:76-83.
248. Abdel-Wahab, Z., C. Weltz, D. Hester, N. Pickett, C. Vervaert, J.R. Barber, D. Jolly, and H.F. Seigler. 1997. A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. *Cancer* 80:401-12.
249. Belli, F., F. Arienti, J. Sule-Suso, C. Clemente, L. Mascheroni, A. Cattelan, C. Santantonio, G.F. Gallino, C. Melani, S. Rao, M.P. Colombo, M. Maio, N. Cascinelli, G. Parmiani, and C. Sanantonio. 1997. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. *Cancer Immunol Immunother* 44:197-203.
250. Veelken, H., A. Mackensen, M. Lahn, G. Kohler, D. Becker, B. Franke, U. Brennscheidt, P. Kulmburg, F.M. Rosenthal, H. Keller, J. Hasse, W. Schultze-Seemann, E.H. Farthmann, R. Mertelsmann, and A. Lindemann. 1997. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. *Int J Cancer* 70:269-77.
251. Arienti, F., F. Belli, F. Napolitano, J. Sulé-Suso, A. Mazzocchi, G.F. Gallino, A. Cattelan, C. Santantonio, L. Rivoltini, C. Melani, M.P. Colombo, N. Cascinelli, M. Maio, G. Parmiani, and C. Sanantonio. 1999. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. *Hum Gene Ther* 10:2907-16.
252. Moller, P., Y. Sun, T. Dorbic, S. Alijagic, A. Makki, K. Jurgovsky, M. Schroff, B.M. Henz, B. Wittig, and D. Schadendorf. 1998. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. *Br J Cancer* 77:1907-16.
253. Sun, Y., K. Jurgovsky, P. Möller, S. Alijagic, T. Dorbic, J. Georgieva, B. Wittig, and D. Schadendorf. 1998. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. *Gene Ther* 5:481-90.
254. Soiffer, R., T. Lynch, M. Mihm, K. Jung, C. Rhuda, J.C. Schmollinger, F.S. Hodi, L. Liebster, P. Lam, S. Mentzer, S. Singer, K.K. Tanabe, A.B. Cosimi, R. Duda, A. Sober, A. Bhan, J. Daley, D. Neuberger, G. Parry, J. Rokovich, L. Richards, J. Drayer, A. Berns, S. Clift, L.K. Cohen, R.C. Mulligan, and G. Dranoff. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* 95:13141-6.
255. Lanzavecchia, A., and F. Sallusto. 2000. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. *Science* 290:92-7.
256. Tamura, Y., P. Peng, K. Liu, M. Daou, and P.K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. *Science* 278:117-120.
257. Chandawarkar, R.Y., M.S. Wagh, and P.K. Srivastava. 1999. The dual nature of specific immunological activity of tumor-derived gp 96 preparations. *J. Exp. Med.* 189:1437-1442.
258. Janetzki, S., D. Palla, V. Rosenhauer, H. Lochs, J.J. Lewis, and P.K. Srivastava. 2000. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. *Int J Cancer* 88:232-8.
259. Oki, Y., and A. Younes. 2004. Heat shock protein-based cancer vaccines. *Expert Rev Vaccines* 3:403-11.
260. Richards, J., A. Testori, E. Whitman, G.B. Mann, J. Lutzky, L. Carnacho, G. Parmiani, A. Hoos, R. Gupta, and P. Srivastava. 2006. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. Meeting of the American Society of Clinical Oncology, Atlanta (USA).
261. Klatzmann, D., P. Cherin, G. Bensimon, O. Boyer, A. Coutellier, F. Charlotte, C. Boccaccio, J.L. Salzmann, and S. Herson. 1998. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. *Hum Gene Ther* 9:2585-94.
262. Dummer, R., J. Bergh, Y. Karlsson, J.A. Horowitz, N.H. Mulder, D.T.B. Huinink, G. Burg, G. Hofbauer, and S. Osanto. 2000. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. *Cancer Gene Ther* 7:1069-76.
263. Kortylewski, M., R. Jove, and H. Yu. 2005. Targeting STAT3 affects melanoma on multiple fronts. *Cancer Metastasis Rev* 24:315-27.
264. Pardoll, D.M., and E.M. Jaffee. 2000. Cancer vaccines: clinical applications, genetically modified tumor vaccines. 3rd ed. In *Principles and Practice of the Biologic Therapy of Cancer*. S.A. Rosenberg, editor. Lippincott Williams & Wilkins, Philadelphia. 647-662.
265. Sotomayor, M.G., H. Yu, S. Antonia, E.M. Sotomayor, and D.M. Pardoll. 2002. Advances in gene therapy for malignant melanoma. *Cancer Control* 9:39-48.

266. Bettinotti, M.P., M.C. Panelli, E. Ruppe, S. Mocellin, G.Q. Phan, D.E. White, and F.M. Marincola. 2003. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. *Int J Cancer* 105:210-6.
267. Jäger, E., S. Gnjatic, Y. Nagata, E. Stockert, D. Jager, J. Karbach, A. Neumann, J. Rieckenberg, Y.T. Chen, G. Ritter, E. Hoffman, M. Arand, L.J. Old, and A. Knuth. 2000. Induction of primary NY-ESO-1 immunity: CD8⁺ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. *Proc Natl Acad Sci U S A* 97:12198-203.
268. Khong, H.T., Q.J. Wang, and S.A. Rosenberg. 2004. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. *J Immunother* 27:184-90.
269. Cormier, J.N., M.L. Salgaller, T. Prevette, K.C. Barracchini, L. Rivoltini, N.P. Restifo, S.A. Rosenberg, and F.M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. *Cancer J Sci Am* 3:37-44.
270. Cebon, J., E. Jager, M.J. Shackleton, P. Gibbs, I.D. Davis, W. Hopkins, S. Gibbs, Q. Chen, J. Karbach, H. Jackson, D.P. MacGregor, S. Sturrock, H. Vaughan, E. Maraskovsky, A. Neumann, E. Hoffman, M.L. Sherman, and A. Knuth. 2003. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. *Cancer Immun* 3:7.
271. Lienard, D., D. Rimoldi, M. Marchand, P.-Y. Dietrich, N. van Baren, C. Geldhof, P. Batard, P. Guillaume, M. Ayyoub, M.J. Pittet, A. Zippelius, K. Fleischhauer, F. Lejeune, J.-C. Cerottini, P. Romero, and D.E. Speiser. 2004. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. *Cancer Immun* 4.
272. Scheibenbogen, C., A. Schmitt, U. Keilholz, T. Allgäuer, U. Hofmann, R. Max, E. Thiel, and D. Schadendorf. 2000. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. *J Immunother* 23:275-81.
273. Lewis, J.J., S. Janetzki, S. Schaed, K.S. Panageas, S. Wang, L. Williams, M. Meyers, L. Butterworth, P.O. Livingston, P.B. Chapman, and A.N. Houghton. 2000. Evaluation of CD8⁺ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. *Int J Cancer* 87:391-8.
274. Salgaller, M.L., F.M. Marincola, J.N. Cormier, and S.A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. *Cancer Res* 56:4749-57.
275. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, and D.E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 4:321-7.
276. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M. Sznol, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, C.A. Seipp, J.H. Einhorn, L. Rogers-Freezer, and D.E. White. 1999. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. *J Immunol* 163:1690-5.
277. Phan, G.Q., C.E. Touloukian, J.C. Yang, N.P. Restifo, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg. 2003. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. *J Immunother* 26:349-56.
278. Slingluff, C.L., Jr., G.R. Petroni, G.V. Yamshchikov, D.L. Barnd, S. Eastham, H. Galavotti, J.W. Patterson, D.H. Deacon, S. Hibbitts, D. Teates, P.Y. Neese, W.W. Grosh, K.A. Chianese-Bullock, E.M. Woodson, C.J. Wiernasz, P. Merrill, J. Gibson, M. Ross, and V.H. Engelhard. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. *J Clin Oncol* 21:4016-26.
279. Jäger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilseemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides *in vivo*: implications for tumor vaccines with melanoma-associated antigens. *Int J Cancer* 66:162-9.
280. Jäger, E., M. Ringhoffer, H.P. Dienes, M. Arand, J. Karbach, D. Jäger, C. Ilseemann, M. Hagedorn, F. Oesch, and A. Knuth. 1996. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides *in vivo*. *Int J Cancer* 67:54-62.

281. Kruit, W.H.J., H.H. van Ojik, J.P. Portielje, R. Verloes, M. Delire, and G. Stoter. 2002. Phase I/II with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. *Proc. Amer. Soc. CLin. Oncol.* 21:11b, Abstract 1854.
282. Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat Med* 2:52-8.
283. Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. Cerundolo, D.F. Nixon, and N. Bhardwaj. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. *J Clin Invest* 104:173-80.
284. Dhodapkar, M.V., R.M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *J Exp Med* 193:233-8.
285. Thurner, B., I. Haendle, C. Röder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, E.B. Bröcker, R.M. Steinman, A. Enk, E. Kämpgen, and G. Schuler. 1999. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 190:1669-78.
286. Tounougou, M., M. Libin, F. Bulté, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman, and T. Velu. 2001. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with Mage-A1/A3-positive tumors. *J Leukoc Biol* 69:937-43.
287. Lau, R., F. Wang, G. Jeffery, V. Marty, J. Kuniyoshi, E. Bade, M.E. Ryback, and J. Weber. 2001. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. *J Immunother* 24:66-78.
288. de Vries, I.J., W.J. Lesterhuis, N.M. Scharenborg, L.P. Engelen, D.J. Ruiter, M.J. Gerritsen, S. Croockewit, C.M. Britten, R. Torensma, G.J. Adema, C.G. Figdor, and C.J. Punt. 2003. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. *Clin Cancer Res* 9:5091-100.
289. Jonuleit, H., A. Giesecke-Tuettenberg, T. Tüting, B. Thurner-Schuler, T.B. Stuge, L. Paragnik, A. Kandemir, P.P. Lee, G. Schuler, J. Knop, and A.H. Enk. 2001. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. *Int J Cancer* 93:243-51.
290. Banchereau, J., A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K.M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman, and J. Fay. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res* 61:6451-8.
291. Banchereau, J., H. Ueno, M. Dhodapkar, J. Connolly, J.P. Finholt, E. Klechevsky, J.P. Blanck, D.A. Johnston, A.K. Palucka, and J. Fay. 2005. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. *J Immunother* 28:505-16.
292. Hersey, P., S.W. Menzies, G.M. Halliday, T. Nguyen, M.L. Farrelly, C. DeSilva, and M. Lett. 2004. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. *Cancer Immunol Immunother* 53:125-34.
293. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 4:328-32.
294. Mackensen, A., B. Herbst, J.-L. Chen, G. Köhler, C. Noppen, W. Herr, G.C. Spagnoli, V. Cerundolo, and A. Lindemann. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34⁺ hematopoietic progenitor cells. *Int. J. Cancer* 86:385-392.
295. Akiyama, Y., R. Tanosaki, N. Inoue, M. Shimada, Y. Hotate, A. Yamamoto, N. Yamazaki, I. Kawashima, I. Nukaya, K. Takesako, K. Maruyama, Y. Takaue, and K. Yamaguchi. 2005. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. *J Transl Med* 3:4-13.
296. Trakatelli, M., M. Tounougou, D. Blocklet, Y. Dodoo, L. Gordower, M. Laporte, P. Vereecken, F. Sales, L. Mortier, N. Mazouz, M. Lambermont, S. Goldman, P. Coulie, M. Goldman, and T. Velu. 2006. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8⁺ T cell responses against NA17-A2 tumor peptide in melanoma patients. *Cancer Immunol Immunother* 55:469-74.
297. de Vries, I.J., M.R. Bernsen, W.J. Lesterhuis, N.M. Scharenborg, S.P. Strijk, M.J. Gerritsen, D.J. Ruiter, C.G. Figdor, C.J. Punt, and G.J. Adema. 2005. Immunomonitoring tumor-specific T cells in delayed-

- type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. *J Clin Oncol* 23:5779-87.
298. Schuler-Thurner, B., E.S. Schultz, T.G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P.O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. *J Exp Med* 195:1279-88.
 299. Chang, A.E., B.G. Redman, J.R. Whitfield, B.J. Nickoloff, T.M. Braun, P.P. Lee, J.D. Geiger, and J.J. Mulé. 2002. A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer. *Clin Cancer Res* 8:1021-32.
 300. O'Rourke, M.G., M. Johnson, C. Lanagan, J. See, J. Yang, J.R. Bell, G.J. Slater, B.M. Kerr, B. Crowe, D.M. Purdie, S.L. Elliott, K.A. Ellem, and C.W. Schmidt. 2003. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. *Cancer Immunol Immunother* 52:387-95.
 301. Salcedo, M., N. Bercovici, R. Taylor, P. Vereecken, S. Massicard, D. Duriau, F. Vernel-Pauillac, A. Boyer, V. Baron-Bodo, E. Mallard, J. Bartholeyns, B. Goxe, N. Latour, S. Leroy, D. Prigent, P. Martiat, F. Sales, M. Laporte, C. Bruyns, J.L. Romet-Lemonne, J.P. Abastado, F. Lehmann, and T. Velu. 2006. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. *Cancer Immunol Immunother* 55:819-29.
 302. Kyte, J.A., L. Mu, S. Aamdal, G. Kvalheim, S. Dueland, M. Hauser, H.P. Gullestad, T. Ryder, K. Lislerud, H. Hammerstad, and G. Gaudernack. 2006. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. *Cancer Gene Ther*.
 303. Escudier, B., T. Dorval, N. Chaput, F. Andre, M.P. Caby, S. Novault, C. Flament, C. Leboulleire, C. Borg, S. Amigorena, C. Boccaccio, C. Bonnerot, O. Dhellin, M. Movassagh, S. Piperno, C. Robert, V. Serra, N. Valente, J.B. Le Pecq, A. Spatz, O. Lantz, T. Tursz, E. Angevin, and L. Zitvogel. 2005. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. *J Transl Med* 3:10.
 304. Ribas, A. 2005. Genetically modified dendritic cells for cancer immunotherapy. *Curr Gene Ther* 5:619-28.
 305. Breckpot, K., C. Heirman, B. Neyns, and K. Thielemans. 2004. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. *J Gene Med* 6:1175-88.
 306. Minami, K., Y. Yamaguchi, A. Ohshita, Y. Kawabuchi, K. Ohta, J. Hihara, and T. Toge. 2005. Generation of antigen-presenting cells using cultured dendritic cells and amplified autologous tumor mRNA. *Oncology* 69:399-407.
 307. Kim, C.J., T. Prevette, J. Cormier, W. Overwijk, M. Roden, N.P. Restifo, S.A. Rosenberg, and F.M. Marincola. 1997. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. *J Immunother* 20:276-86.
 308. Butterfield, L.H., S.M. Jilani, N.G. Chakraborty, L.A. Bui, A. Ribas, V.B. Disette, R. Lau, S.C. Gamradt, J.A. Glaspy, W.H. McBride, B. Mukherji, and J.S. Economou. 1998. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. *J Immunol* 161:5607-13.
 309. Delcayre, A., and J.B. Le Pecq. 2006. Exosomes as novel therapeutic nanodevices. *Curr Opin Mol Ther* 8:31-8.
 310. Taieb, J., N. Chaput, N. Scharzt, S. Roux, S. Novault, C. Menard, F. Ghiringhelli, M. Terme, A.F. Carpentier, G. Darrasse-Jese, F. Lemonnier, and L. Zitvogel. 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. *J Immunol* 176:2722-9.
 311. Mazumder, A., and S.A. Rosenberg. 1984. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. *J Exp Med* 159:495-507.
 312. Rosenberg, S.A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. *Science* 233:1318-21.
 313. Marincola, F.M., E.M. Jaffee, D.J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Adv Immunol* 74:181-273.
 314. Economou, J.S., A.S. Beldegrun, J. Glaspy, E.M. Toloza, R. Figlin, J. Hobbs, N. Meldon, R. Kaboo, C.L. Tso, A. Miller, R. Lau, W. McBride, and R.C. Moen. 1996. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. *J Clin Invest* 97:515-21.
 315. Roszkowski, J.J., G.E. Lyons, W.M. Kast, C. Yee, K. Van Besien, and M.I. Nishimura. 2005. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. *Cancer Res* 65:1570-6.

316. Duval, L., H. Schmidt, K. Kaltoft, K. Fode, J.J. Jensen, S.M. Sorensen, M.I. Nishimura, and H. von der Maase. 2006. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. *Clin Cancer Res* 12:1229-36.
317. Montes, M., N. Rufer, V. Appay, S. Reynard, M.J. Pittet, D.E. Speiser, P. Guillaume, J.C. Cerottini, P. Romero, and S. Leyvraz. 2005. Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. *Clin Exp Immunol* 142:292-302.
318. Grimm, E.A., A. Mazumder, H.Z. Zhang, and S.A. Rosenberg. 1982. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. *J Exp Med* 155:1823-41.
319. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, C.A. Seipp, C. Simpson, and C.M. Reichert. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 313:1485-92.
320. Rosenberg, S.A. 1990. Adoptive immunotherapy for cancer. *Sci Am* 262:34-41.
321. Dillman, R.O., R.K. Oldham, N.M. Barth, R.J. Cohen, D.R. Minor, R. Birch, J.R. Yannelli, J.R. Maleckar, A. Sferruzza, J. Arnold, and et al. 1991. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. *Cancer* 68:1-8.
322. Rosenberg, S.A., B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, and et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N Engl J Med* 319:1676-80.
323. Rosenberg, S.A., J.R. Yannelli, J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, D.R. Parkinson, C.A. Seipp, J.H. Einhorn, and D.E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. *J Natl Cancer Inst* 86:1159-66.
324. Ravaud, A., E. Legrand, M.M. Delaunay, E. Bussieres, V. Coulon, L. Cany, S. Huet, D. Verdier, M. Kind, F. Chomy, and et al. 1995. A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. *Br J Cancer* 71:331-6.
325. Goedegebuure, P.S., L.M. Douville, H. Li, G.C. Richmond, D.D. Schoof, M. Scavone, and T.J. Eberlein. 1995. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. *J Clin Oncol* 13:1939-49.
326. Mitchell, M.S., D. Darrach, D. Yeung, S. Halpern, A. Wallace, J. Volland, V. Jones, and J. Kan-Mitchell. 2002. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. *J Clin Oncol* 20:1075-86.
327. Dudley, M.E., J. Wunderlich, M.I. Nishimura, D. Yu, J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, R. Sherry, S.F. Leitman, and S.A. Rosenberg. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. *J Immunother* 24:363-73.
328. Yee, C., J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, E. Celis, and P.D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. *Proc Natl Acad Sci U S A* 99:16168-73.
329. Dudley, M.E., J.R. Wunderlich, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R.M. Sherry, F.M. Marincola, S.F. Leitman, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, A. Nahvi, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. *J Immunother* 25:243-51.
330. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, M.R. Robinson, M. Raffeld, P. Duray, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 298:850-4.
331. Dudley, M.E., J.R. Wunderlich, J.C. Yang, R.M. Sherry, S.L. Topalian, N.P. Restifo, R.E. Royal, U. Kammula, D.E. White, S.A. Mavroukakis, L.J. Rogers, G.J. Gracia, S.A. Jones, D.P. Manganelli, M.M. Pelletier, J. Gea-Banacloche, M.R. Robinson, D.M. Berman, A.C. Filie, A. Abati, and S.A. Rosenberg. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *J Clin Oncol* 23:2346-57.

332. Yee, C., M.J. Gilbert, S.R. Riddell, V.G. Brichard, A. Fefer, J.A. Thompson, T. Boon, and P.D. Greenberg. 1996. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. *J Immunol* 157:4079-86.
333. Yee, C., P.A. Savage, P.P. Lee, M.M. Davis, and P.D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. *J Immunol* 162:2227-34.
334. Valmori, D., M.J. Pittet, D. Rimoldi, D. Liénard, R. Dunbar, V. Cerundolo, F. Lejeune, J.C. Cerottini, and P. Romero. 1999. An antigen-targeted approach to adoptive transfer therapy of cancer. *Cancer Res* 59:2167-73.
335. Yee, C., J.A. Thompson, P. Roche, D.R. Byrd, P.P. Lee, M. Piepkorn, K. Kenyon, M.M. Davis, S.R. Riddell, and P.D. Greenberg. 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. *J Exp Med* 192:1637-44.
336. Dieckmann, D., H. Plottner, S. Berchtold, T. Berger, and G. Schuler. 2001. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. *J Exp Med* 193:1303-10.
337. Rosenberg, S.A., and M.E. Dudley. 2004. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci U S A* 101 Suppl 2:14639-45.
338. Robbins, P.F., M.E. Dudley, J. Wunderlich, M. El-Gamil, Y.F. Li, J. Zhou, J. Huang, D.J. Powell, Jr., and S.A. Rosenberg. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *J Immunol* 173:7125-30.
339. Zhou, J., X. Shen, J. Huang, R.J. Hodes, S.A. Rosenberg, and P.F. Robbins. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. *J Immunol* 175:7046-52.
340. Dréno, B., J.M. Nguyen, A. Khammari, M.C. Pandolfino, M.H. Tessier, S. Bercegeay, A. Cassidanius, P. Lemarre, S. Billaudel, N. Labarrière, and F. Jotereau. 2002. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. *Cancer Immunol Immunother* 51:539-46.
341. Labarrière, N., M.C. Pandolfino, N. Gervois, A. Khammari, M.H. Tessier, B. Dréno, and F. Jotereau. 2002. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. *Cancer Immunol Immunother* 51:532-8.
342. Benlalam, H., V. Vignard, A. Khammari, A. Bonnin, Y. Godet, M.C. Pandolfino, F. Jotereau, B. Dreno, and N. Labarriere. 2006. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. *Cancer Immunol Immunother*.
343. Rosenberg, S.A., J.C. Yang, and N.P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. *Nat Med* 10:909-15.
344. Coulie, P.G., V. Karanikas, C. Lurquin, D. Colau, T. Connerotte, T. Hanagiri, A. Van Pel, S. Lucas, D. Godelaine, C. Lonchay, M. Marchand, N. Van Baren, and T. Boon. 2002. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. *Immunol Rev* 188:33-42.
345. Godelaine, D., J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P.G. Coulie, G. Schuler, T. Boon, and A. Van Pel. 2003. Polyclonal cytolytic T lymphocyte responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. *J Immunol* 171:4893-7.
346. Karanikas, V., C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethé, T. Connerotte, V. Corbière, M.-A. Demoitie, D. Liénard, B. Dréno, T. Velu, T. Boon, and P.G. Coulie. 2003. Monoclonal Anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. *J Immunol* 171:4898-904.
347. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, N. van Baren, and T. Boon. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. *Proc Natl Acad Sci U S A* 101 Suppl 2:14631-8.
348. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethe, E. De Plaen, T. Velu, T. Boon, and P.G. Coulie. 2005. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. *J Exp Med* 201:241-8.
349. Lurquin, C., B. Lethe, E. De Plaen, V. Corbiere, I. Theate, N. van Baren, P.G. Coulie, and T. Boon. 2005. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. *J Exp Med* 201:249-57.
350. Vansteenkiste, J., M. Zielinski, J. Dahabre, A. Linder, W. Malinowski, J. Jassem, E. Esteban, M. Lopez-Brea, B. Passlick, F. Lehman, and V. Brichard. 2006. Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the recombinant MAGE-A3 compound as adjuvant therapy

- in completely resected stages IB/II MAGE-A3 positive NSCLC. American Society of Clinical Oncology, Atlanta, USA.
351. Pure, E., J.P. Allison, and R.D. Schreiber. 2005. Breaking down the barriers to cancer immunotherapy. *Nat Immunol* 6:1207-10.
 352. Sensi, M., C. Farina, C. Maccalli, A. Anichini, D. Berd, and G. Parmiani. 1998. Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. *J Immunother* 21:198-204.
 353. Boon, T., P.G. Coulie, B.J. Van den Eynde, and P. van der Bruggen. 2006. Human T Cell Responses Against Melanoma. *Annu Rev Immunol* 24:175-208.
 354. Lehmann, P.V., T. Forsthuber, A. Miller, and E.E. Sercarz. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. *Nature* 358:155-7.
 355. Markiewicz, M.A., F. Fallarino, A. Ashikari, and T.F. Gajewski. 2001. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. *Int Immunol* 13:625-32.
 356. Uebel, S., and R. Tampe. 1999. Specificity of the proteasome and the TAP transporter. *Curr Opin Immunol* 11:203-8.
 357. Morel, S., F. Lévy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A.L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.C. Cerottini, T. Boon, J.E. Gairin, and B.J. Van den Eynde. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. *Immunity* 12:107-17.
 358. Van den Eynde, B.J., and S. Morel. 2001. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. *Curr Opin Immunol* 13:147-53.
 359. Jain, R.K., G.C. Koenig, M. Dellian, D. Fukumura, L.L. Munn, and R.J. Melder. 1996. Leukocyte-endothelial adhesion and angiogenesis in tumors. *Cancer Metastasis Rev* 15:195-204.
 360. Piali, L., A. Fichtel, H.J. Terpe, B.A. Imhof, and R.H. Gisler. 1995. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. *J Exp Med* 181:811-6.
 361. Inge, T.H., S.K. Hoover, B.M. Susskind, S.K. Barrett, and H.D. Bear. 1992. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. *Cancer Res* 52:1386-92.
 362. Renauld, J.-C. 2003. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. *Nat Rev Immunol* 3:667-76.
 363. Uyttenhove, C., L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. *Nat Med* 9:1269-74.
 364. Chambers, C.A., M.F. Krummel, B. Boitel, A. Hurwitz, T.J. Sullivan, S. Fournier, D. Cassell, M. Brunner, and J.P. Allison. 1996. The role of CTLA-4 in the regulation and initiation of T-cell responses. *Immunol Rev* 153:27-46.
 365. Woo, E.Y., C.S. Chu, T.J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S.C. Rubin, L.R. Kaiser, and C.H. June. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res* 61:4766-72.
 366. Liyanage, U.K., T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J.A. Drebin, S.M. Strasberg, T.J. Eberlein, P.S. Goedegebuure, and D.C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. *J Immunol* 169:2756-61.
 367. Ghiringhelli, F., C. Menard, M. Terme, C. Flament, J. Taieb, N. Chaput, P.E. Puig, S. Novault, B. Escudier, E. Vivier, A. Lécésne, C. Robert, J.Y. Blay, J. Bernard, S. Caillat-Zucman, A. Freitas, T. Tursz, O. Wagner-Ballon, C. Capron, W. Vainchenker, F. Martin, and L. Zitvogel. 2005. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. *J Exp Med* 202:1075-85.
 368. Ramirez-Montagut, T., A. Chow, D. Hirschhorn-Cymerman, T.H. Terwey, A.A. Kochman, S. Lu, R.C. Miles, S. Sakaguchi, A.N. Houghton, and M.R. van den Brink. 2006. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. *J Immunol* 176:6434-42.
 369. Wang, H.Y., D.A. Lee, G. Peng, Z. Guo, Y. Li, Y. Kuniwa, E.M. Shevach, and R.F. Wang. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. *Immunity* 20:107-18.
 370. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. *Science* 274:1363-6.
 371. Lang, K.S., M. Recher, T. Junt, A.A. Navarini, N.L. Harris, S. Freigang, B. Odermatt, C. Conrad, L.M. Ittner, S. Bauer, S.A. Luther, S. Uematsu, S. Akira, H. Hengartner, and R.M. Zinkernagel. 2005. Toll-

- like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. *Nat Med* 11:138-45.
372. Gogas, H., J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, C. Markopoulos, D. Bafaloukos, D. Pectasides, G. Fountzilas, and J.M. Kirkwood. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. *N Engl J Med* 354:709-18.
 373. Weber, J.S. 2006. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. *Melanoma Res* 16:379-83.
 374. Hodi, F.S., M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, M.V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, R. Padera, M.T. Jaklitsch, S. Shankar, T.C. Chen, A. Korman, J.P. Allison, and G. Dranoff. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. *Proc Natl Acad Sci U S A* 100:4712-7.
 375. Phan, G.Q., J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, N.P. Restifo, L.R. Haworth, C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, P.H. Duray, S.M. Steinberg, J.P. Allison, T.A. Davis, and S.A. Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* 100:8372-8377.
 376. Attia, P., G.Q. Phan, A.V. Maker, M.R. Robinson, M.M. Quezado, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, N.P. Restifo, L.R. Haworth, C. Levy, S.A. Mavroukakis, G. Nichol, M.J. Yellin, and S.A. Rosenberg. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. *J Clin Oncol* 23:6043-53.
 377. Ribas, A., L.H. Camacho, G. Lopez-Berestein, D. Pavlov, C.A. Bulanhagui, R. Millham, B. Comin-Anduix, J.M. Reuben, E. Seja, C.A. Parker, A. Sharma, J.A. Glaspy, and J. Gomez-Navarro. 2005. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. *J Clin Oncol* 23:8968-77.
 378. Fischkoff, S., E. Hersh, J. Weber, J. Powderly, K. Khan, A. Pavlick, W. Samlowski, S. O'Day, G. Nichol, and M. Yellin. 2005. Durable responses and progression-free survival in observed in a phase II study of MDX-010 alone or in combination with Dacarbazine (DTIC) in metastatic melanoma. *Proc Amer Soc Clin Oncol*.
 379. Maker, A.V., G.Q. Phan, P. Attia, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, L.R. Haworth, C. Levy, D. Kleiner, S.A. Mavroukakis, M. Yellin, and S.A. Rosenberg. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. *Ann Surg Oncol* 12:1005-16.
 380. Sanderson, K., R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, M. Yellin, and J. Weber. 2005. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. *J Clin Oncol* 23:741-50.
 381. Lutsiak, M.E., R.T. Semnani, R. De Pascalis, S.V. Kashmiri, J. Schlom, and H. Sabzevari. 2005. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. *Blood* 105:2862-8.
 382. Ercolini, A.M., B.H. Ladle, E.A. Manning, L.W. Pfannenstiel, T.D. Armstrong, J.P. Machiels, J.G. Bieler, L.A. Emens, R.T. Reilly, and E.M. Jaffee. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. *J Exp Med* 201:1591-602.
 383. Attia, P., A.V. Maker, L.R. Haworth, L. Rogers-Freezer, and S.A. Rosenberg. 2005. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. *J Immunother* 28:582-92.
 384. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1:27-31.
 385. Grover, R., and G.D. Wilson. 1996. Bcl-2 expression in malignant melanoma and its prognostic significance. *Eur J Surg Oncol* 22:347-9.
 386. Jansen, B., V. Wacheck, E. Heere-Ress, H. Schlagbauer-Wadl, C. Hoeller, T. Lucas, M. Hoermann, U. Hollenstein, K. Wolff, and H. Pehamberger. 2000. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. *Lancet* 356:1728-33.
 387. Kashani-Sabet, M., R.W. Sagebiel, C.M. Ferreira, M. Nosrati, and J.R. Miller, 3rd. 2002. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. *J Clin Oncol* 20:1826-31.
 388. Ugurel, S., G. Rapp, W. Tilgen, and U. Reinhold. 2001. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. *J Clin Oncol* 19:577-83.

389. Lev, D.C., A. Onn, V.O. Melinkova, C. Miller, V. Stone, M. Ruiz, E.C. McGary, H.N. Ananthaswamy, J.E. Price, and M. Bar-Eli. 2004. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. *J Clin Oncol* 22:2092-100.
390. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 350:2335-42.